[{"address1": "200-3650 Gilmore Way", "city": "Burnaby", "state": "BC", "zip": "V5G 4W8", "country": "Canada", "phone": "604 484 3300", "fax": "604 484 3450", "website": "https://www.xenon-pharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada. Its product candidates include Azetukalner, a selective Kv7 potassium channel opener in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.", "fullTimeEmployees": 316, "companyOfficers": [{"maxAge": 1, "name": "Mr. Ian C. Mortimer C.M.A., CPA, M.B.A.", "age": 48, "title": "President, CEO & Director", "yearBorn": 1976, "fiscalYear": 2023, "totalPay": 1066715, "exercisedValue": 2366401, "unexercisedValue": 29581198}, {"maxAge": 1, "name": "Ms. Sherry  Aulin C.A., CPA", "age": 40, "title": "Chief Financial Officer", "yearBorn": 1984, "fiscalYear": 2023, "totalPay": 664799, "exercisedValue": 0, "unexercisedValue": 4300444}, {"maxAge": 1, "name": "Dr. Robin P. Sherrington Ph.D.", "age": 63, "title": "Executive Vice President of Strategy & Innovation", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 587028, "exercisedValue": 0, "unexercisedValue": 9907717}, {"maxAge": 1, "name": "Dr. Christopher John Kenney M.D.", "age": 53, "title": "Chief Medical Officer", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 719820, "exercisedValue": 0, "unexercisedValue": 3669313}, {"maxAge": 1, "name": "Dr. Matthew D. Ronsheim Ph.D.", "age": 51, "title": "Chief Operating Officer", "yearBorn": 1973, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Andrea  DiFabio J.D.", "age": 56, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 200510, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Shelley  McCloskey B.A.", "age": 64, "title": "Executive Vice President of Human Resources", "yearBorn": 1960, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. James R. Empfield Ph.D.", "age": 63, "title": "Executive Vice President of Drug Discovery", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 323428, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 30.73, "open": 30.7, "dayLow": 29.65, "dayHigh": 31.585, "regularMarketPreviousClose": 30.73, "regularMarketOpen": 30.7, "regularMarketDayLow": 29.65, "regularMarketDayHigh": 31.585, "payoutRatio": 0.0, "beta": 1.215, "forwardPE": -8.820225, "volume": 867744, "regularMarketVolume": 867744, "averageVolume": 577066, "averageVolume10days": 1216350, "averageDailyVolume10Day": 1216350, "bid": 31.23, "ask": 31.53, "bidSize": 1, "askSize": 1, "marketCap": 2403443968, "fiftyTwoWeekLow": 26.74, "fiftyTwoWeekHigh": 46.0, "fiftyDayAverage": 35.9569, "twoHundredDayAverage": 39.462624, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 1785554304, "profitMargins": 0.0, "floatShares": 70775310, "sharesOutstanding": 76542800, "sharesShort": 3947500, "sharesShortPriorMonth": 3760703, "sharesShortPreviousMonthDate": 1740700800, "dateShortInterest": 1743379200, "sharesPercentSharesOut": 0.051599998, "heldPercentInsiders": 0.00373, "heldPercentInstitutions": 1.03355, "shortRatio": 7.82, "shortPercentOfFloat": 0.0519, "impliedSharesOutstanding": 78534800, "bookValue": 9.879, "priceToBook": 3.1784594, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -234330000, "trailingEps": -3.01, "forwardEps": -3.56, "enterpriseToEbitda": -6.452, "52WeekChange": -0.2398935, "SandP52WeekChange": 0.059571505, "quoteType": "EQUITY", "currentPrice": 31.4, "targetHighPrice": 65.0, "targetLowPrice": 42.0, "targetMeanPrice": 57.8125, "targetMedianPrice": 60.0, "recommendationMean": 1.29412, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 16, "totalCash": 626905024, "totalCashPerShare": 8.19, "ebitda": -276737984, "totalDebt": 9015000, "quickRatio": 17.656, "currentRatio": 17.85, "debtToEquity": 1.194, "returnOnAssets": -0.19803, "returnOnEquity": -0.2785, "grossProfits": -210394000, "freeCashflow": -117591248, "operatingCashflow": -181388992, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "XENE", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "regularMarketChangePercent": 2.1802802, "regularMarketPrice": 31.4, "shortName": "Xenon Pharmaceuticals Inc.", "longName": "Xenon Pharmaceuticals Inc.", "postMarketTime": 1744402800, "regularMarketTime": 1744401600, "exchange": "NGM", "messageBoardId": "finmb_565718", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "marketState": "CLOSED", "corporateActions": [], "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1415197800000, "postMarketChangePercent": 0.0, "postMarketPrice": 31.4, "postMarketChange": 0.0, "regularMarketChange": 0.6700001, "regularMarketDayRange": "29.65 - 31.585", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 577066, "fiftyTwoWeekLowChange": 4.66, "fiftyTwoWeekLowChangePercent": 0.17427075, "fiftyTwoWeekRange": "26.74 - 46.0", "fiftyTwoWeekHighChange": -14.6, "fiftyTwoWeekHighChangePercent": -0.3173913, "fiftyTwoWeekChangePercent": -23.98935, "earningsTimestamp": 1740690060, "earningsTimestampStart": 1746615540, "earningsTimestampEnd": 1747051200, "earningsCallTimestampStart": 1740691800, "earningsCallTimestampEnd": 1740691800, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -3.01, "epsForward": -3.56, "epsCurrentYear": -4.06604, "priceEpsCurrentYear": -7.7225013, "fiftyDayAverageChange": -4.556902, "fiftyDayAverageChangePercent": -0.12673233, "twoHundredDayAverageChange": -8.062624, "twoHundredDayAverageChangePercent": -0.20431039, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.3 - Strong Buy", "cryptoTradeable": false, "displayName": "Xenon Pharmaceuticals", "trailingPegRatio": null, "__fetch_time": "2025-04-12"}]